Amazon Biotech secures letter of intent to fund clinical trials of AMZ-0026 for AIDS

By Angela McDaniels

Seattle, Nov. 30 - Amazon Biotech Inc. said it has secured a letter of intent from a U.S. medical center to fund the phase 2 and phase 3 trials for its investigational immune modulator AIDS drug, AMZ-0026.

The medical center will receive a percentage of royalties if and when the drug is approved.

"This is a big vote of confidence in Amazon Biotech and in its drug AMZ-0026. Besides the funding for the studies, we will be getting the expertise and resources of a major medical center that has significant experience in running clinical trials and in the FDA drug approval process," said Mechael Kanovsky, Amazon Biotech chief executive officer, in a company news release.

Based in New York, Amazon Biotech is a natural plant pharmaceutical company focused on the development of immune modulator drugs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.